Imunon, Inc. Files Q2 2024 10-Q Report
Ticker: IMNN · Form: 10-Q · Filed: Aug 14, 2024 · CIK: 749647
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Imunon (formerly Celsion) filed its Q2 2024 10-Q. Check financials.
AI Summary
Imunon, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Celsion Corp, is in the pharmaceutical preparations industry. Financial details and operational updates for the second quarter of 2024 are provided in this filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational status of Imunon, Inc. for the second quarter of 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Imunon faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20240814 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Imunon, Inc. (company) — Filer of the 10-Q
- Celsion Corp (company) — Former name of Imunon, Inc.
- 20240630 (date) — End of the reporting period
- 20240814 (date) — Filing date of the 10-Q
FAQ
What is the primary business of Imunon, Inc.?
Imunon, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
What was Imunon, Inc. formerly known as?
Imunon, Inc. was formerly known as Celsion Corp, with previous name changes from CELSION CORP and CHEUNG LABORATORIES INC.
For what period is this 10-Q report filed?
This 10-Q report is filed for the period ending June 30, 2024.
When was this 10-Q report filed with the SEC?
This 10-Q report was filed on August 14, 2024.
What is the state of incorporation for Imunon, Inc.?
Imunon, Inc. is incorporated in Delaware (DE).
Filing Stats: 4,432 words · 18 min read · ~15 pages · Grade level 17.3 · Accepted 2024-08-14 09:00:26
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Mark
Filing Documents
- form10-q.htm (10-Q) — 893KB
- ex31-1.htm (EX-31.1) — 19KB
- ex31-2.htm (EX-31.2) — 20KB
- ex32-1.htm (EX-32.1) — 8KB
- 0001493152-24-031916.txt ( ) — 4478KB
- imnn-20240630.xsd (EX-101.SCH) — 34KB
- imnn-20240630_cal.xml (EX-101.CAL) — 48KB
- imnn-20240630_def.xml (EX-101.DEF) — 143KB
- imnn-20240630_lab.xml (EX-101.LAB) — 332KB
- imnn-20240630_pre.xml (EX-101.PRE) — 267KB
- form10-q_htm.xml (XML) — 530KB
: FINANCIAL INFORMATION
PART I: FINANCIAL INFORMATION Item 1.
Financial Statements
Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 1 Condensed Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2024 and 2023 3 Condensed Consolidated Statements of Comprehensive Loss (Unaudited) for the Three and Six Months Ended June 30, 2024 and 2023 4 Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2024 and 2023 5 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) for the Three Months Ended June 30, 2024 and 2023 7 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) for the Six Months Ended June 30, 2024 and 2023 8 Notes to the Condensed Consolidated Financial Statements (Unaudited) 9 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 35 Item 4.
Controls and Procedures
Controls and Procedures 35
: OTHER INFORMATION
PART II: OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 36 Item 1A.
Risk Factors
Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 3. Defaults Upon Senior Securities 36 Item 4. Mine Safety Disclosures 36 Item 5. Other Information 36 Item 6. Exhibits 37
SIGNATURES
SIGNATURES 38 Cautionary Note Regarding Forward-Looking Statements This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of this Quarterly Report on Form 10-Q, including, without limitation, any projections of earnings, revenue or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, pre-clinical development, clinical trials, manufacturing and commercialization), uncertainties and assumptions regarding any continuing impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, any statements concerning proposed drug candidates, potential therapeutic benefits, or other new products or services, any statements regarding future economic conditions or performance, any changes in the course of research and development activities and in clinical trials, any possible changes in cost and timing of development and testing, capital structure, financial condition, working capital needs and other financial items, and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified using terminology such as "may," "will," "expects," "plans," "anticipates," "estimates," "potential" or "continue," or the negative thereof or other comparable terminology. Although we believe that our expectations are based on reasonable assumptions within the bounds of our knowledge of our industry, business, and operations, we cannot guarantee that actual results will not differ materially from our expectations. Our future financial condition and results of operations, as well as any forward-looking st